

17 October 2025

Dear Shareholders

Annual General Meeting

Orbital Corporation Limited ACN 009 344 058 (**Orbital** or **Company**) advises that its 2025 Annual General Meeting is scheduled to be held in person at 10:00 (AWST) on Thursday, 20 November 2025 at Stirling Leisure Centre, 38 Ashbury Crescent, Mirrabooka WA 6061 (**Meeting**).

In the interest of efficiency and reducing the environmental impact of printing and shipment, and as permitted by the *Corporations Act 2001* (Cth), the Company will not be dispatching physical copies of the Notice of Meeting unless the shareholder has made a valid election to receive documents in hard copy.

The Notice of Meeting can be viewed and downloaded from the link set below.

A Proxy Form in relation to the Meeting is included with this letter. The Company strongly encourages Shareholders to lodge a directed proxy form prior to the Meeting and register their attendance to the Meeting should they wish to attend. Completed Proxy Forms must be returned to and received by the Company's Share Registry, MUFG Corporate Markets (AU) Limited, by 10:00am (AWST) on Tuesday, 18 November 2025, in accordance with the instructions on the Proxy Form.

Questions should also be submitted in advance of the Meeting as this will provide management with the best opportunity to prepare for the meeting, for example by preparing answers in advance to Shareholders' questions. Voting and questions may also be submitted during the Meeting.

Please find below the link to important Meeting documents:

Notice of Meeting and Explanatory Statement: https://orbitaluav.com/investors/www.orbitaluav.com/investors

Alternatively, a complete copy of the document is available from the ASX announcements platform.

If you have nominated an email address and have elected to receive electronic communications from the Company, you will receive an email to your nominated email address with a link to an electronic copy of the important Meeting documents.

In order to receive electronic communications from the Company in the future, please update your Shareholder details online at https://au.investorcentre.mpms.mufg.com and Register as a member with your unique shareholder identification number and postcode (or country for overseas residents).

If you are unable to access any of the important Meeting documents online, please contact the Company Secretary on +61 8 9441 2135 or via email at mwege@orbitalcorp.com.au.

If it becomes necessary or appropriate to make alternative arrangements to those set out in the Company's Notice of Meeting, the Company will notify Shareholders accordingly via the Company's website at https://orbitaluav.com/ and the Company's ASX Announcement Platform at www.asx.com.au (ASX: OEC).

This announcement is authorised for market release by the Board of Orbital Corporation Limited.

Sincerely,

Mark Wege

CFO | Company Secretary Orbital Corporation Limited

ORBITAL CORPORATION LIMITED

ABN 32 009 344 058

Notice of 2025 Annual General Meeting

10:00am (AWST), Thursday 20 November 2025

Stirling Leisure Centre

38 Ashbury Crescent

Mirrabooka WA 6061

1

Orbital Corporation Limited NOTICE OF 2025 ANNUAL GENERAL MEETING

The 2025 Annual General Meeting of Orbital Corporation Limited ACN 009 344 058 (Orbital or the Company) will be held at 10:00am (AWST) on Thursday 20 November 2025 at the Stirling Leisure Centre, 38 Ashbury Crescent, Mirrabooka WA 6061.

Dear Shareholder

It is my pleasure to invite you to attend Orbital's Annual General Meeting (**AGM**) to be held at 10.00am Australian Western Standard Time (**AWST**) on Thursday 20 November 2025 at the Stirling Leisure Centre 38 Ashbury Crescent, Mirrabooka WA 6061 (**Meeting**).

As a Shareholder your participation at the Meeting is important. The Meeting is an opportunity to engage directly with Orbital's Board and senior management team and I encourage you to attend.

US Department of Defense UAV strategies and associated procurement policies are currently in transition.

In June 2025 the US President signed Executive Order 14307, aiming to enhance the United States' leadership in drone technology by accelerating the integration and commercialisation of drones into the national airspace. This includes investment of USD 150 billion in UAV funding through 2032 across military and commercial segments.

This transition will take some time to be implemented by the US Department of Defense, and as such the Board cannot fully assess the impact on the Company at this time.

However, the Company is well positioned to meet the increased demand expected to flow through from this decision as we are fully aligned to UAS compliance requirements and have an existing manufacturing facility in the US that can be re-activated within the next 12-months.

The rapidly evolving UAV market demands include:

- Increased payload requirements creating strong demand for higher-capacity engines across both military and commercial UAV markets:
- Vertical take-off and landing (VTOL) configurations in both military and commercial market sectors requiring high-voltage battery charging, further accelerating the shift toward more powerful engines; and
- Beyond Visual Line of Sight (BVLOS) regulations that are driving the need for increased system safety and reliability, accelerating the adoption toward heavy fuels and military-grade performance standards in the commercial market.

An electronic copy of the Company's 2025 Annual Report is available to download or view on Orbital's website at: https://orbitaluav.com/. Hard copies have been sent to those Shareholders who previously elected to receive the report in this format.

This Notice of Meeting details the items of business to be conducted at the AGM. Your Directors believe that each of the resolutions is in the best interests of the Company and its Shareholders. Voting on the resolutions at the Meeting is important and if you are not able to attend, I encourage you to exercise your voting rights by completing and returning the enclosed Proxy Form. If you nominate a proxy, please carefully consider the related comments in this Notice.

Completed Proxy Forms must be returned to and received by the Company's Share Registry, MUFG Corporate Markets (AU) Limited, by 10:00am (AWST) on Tuesday 18 November 2025. This can be done either by posting the enclosed form or lodging it online at https://au.investorcentre.mpms.mufg.com

On behalf of the Board and management team I look forward to your company at the Meeting.

Yours faithfully

Mulhat

Kyle Abbott

Chair

17 October 2025

Orbital Corporation Limited NOTICE OF 2025 ANNUAL GENERAL MEETING

Items	of Business (Items)	Shareholder Approval	Voting Restrictions and Further Details	
ORDII	NARY BUSINESS			
1.	CHAIR & CEO ADDRESS	The Chair and CEO will provide a presentation on the performance of the Company during the financial year ended 30 June 2025 and outline the strategic operational activities of the Company.	Not applicable	5
2.	DISCUSSION OF FINANCIAL STATEMENTS AND REPORTS	To receive and consider the Financial Report, Directors' Report and Auditor's Report for the year ended 30 June 2025.	Not applicable	5
3.	REMUNERATION REPORT	To adopt the Remuneration Report for the year ended 30 June 2025.	Non-binding	5
4.	RE-ELECTION OF DIRECTOR – MR STEVE GALLAGHER	That, for the purposes of Listing Rule 14.4, clause 7.3(c) of the Constitution and for all other purposes, Mr Steve Gallagher be re-elected as a Director.	Ordinary resolution	5
5.	ELECTION OF DIRECTOR - MR ANDREW MILLS	That, for the purposes of Listing Rule 14.4, clause 7.3(j) of the Constitution and for all other purposes, Mr Andrew Mills, having been appointed to the Board since the last annual general meeting of the Company, ceases to hold office and, being eligible, is elected as a Director.	Ordinary resolution	6
SPEC	IAL BUSINESS			
6.	RATIFY THE ISSUE OF PLACEMENT SHARES UNDER LISTING RULE 7.1	That, pursuant to and in accordance with Listing Rule 7.4 and for all other purposes, Shareholders approve and ratify the prior issue of 14,285,715 Shares under Listing Rule 7.1 on the terms and conditions in the Explanatory Notes.	Ordinary resolution	6
7.	ADDITIONAL CAPACITY TO ISSUE EQUITY SECURITIES	That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, Shareholders authorise and approve the issue of equity securities (as defined in the Listing Rules, Equity Securities) of up to 10% of the issued capital of the Company (at the time of the issue) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions in the Explanatory Notes.	Special resolution	7

Orbital Corporation Limited

NOTICE OF 2025 ANNUAL GENERAL MEETING

VOTING

Voting Entitlement

The Company's shareholders (**Shareholders**) recorded on the Company's register of members at 4:00pm (AWST) on Tuesday 18 November 2025 (**Voting Entitlement Date**) will be entitled to vote on Items at the Company's 2025 annual general meeting (**Meeting**).

Becoming a Shareholder

Persons who become registered Shareholders between the date of this notice of meeting (**Notice**) and the Voting Entitlement Date and wish to vote at the Meeting by proxy should call +61 1300 554 474 and request an additional personalised voting form.

Persons who become beneficial Shareholders between the date of this Notice and the Voting Entitlement Date and wish to vote at the Meeting by proxy should contact their broker or intermediary for instructions on how to do so.

Voting Procedure

Under the Company's constitution as at the date of this Notice (**Constitution**), each poll will be conducted as directed by the chair of the Meeting (the **Chair**).

Shareholders can vote in one of two ways:

- · by attending the Meeting and voting; or
- by appointing a proxy to attend and vote on their behalf.

Shareholders are asked to arrive at the venue 15 minutes prior to the time designated for the Meeting, if possible, so that the Company may check their Shareholding against the Company's share register and note attendances.

Voting Restrictions

The voting prohibitions under the *Corporations Act 2001* (Cth) (**Corporations Act**) and voting exclusions under the ASX Listing Rules (**Listing Rules**) for each Item are set out in the Explanatory Notes to this Notice.

PROXY FORMS

Proxy Form

Enclosed with this Notice is a personalised proxy form (**Proxy Form**). The Proxy Form allows Shareholders who are not attending the Meeting to appoint a proxy to vote on their behalf.

If you hold fully paid ordinary shares in the capital of the Company (**Shares**) in more than one capacity, please complete the Proxy Form that is relevant to each holding.

Appointing proxies

Shareholders who are entitled to attend and vote at the Meeting, may appoint a proxy to act generally at the Meeting and to vote on their behalf.

A proxy need not be a Shareholder of the Company.

A Shareholder entitled to attend and vote can appoint up to two proxies, and should specify the proportion or number of votes each proxy is appointed and authorised to exercise. If no proportion or number is specified, each proxy may exercise half of the Shareholder's votes. If you wish to appoint two proxies please call +61 1300 554 474 and request an additional Proxy Form.

A corporate Shareholder or proxy must appoint a person as its corporate representative.

Undirected proxies

Any proxy given to:

 a member of the Company's key management personnel (those persons having authority and responsibility for planning, directing and controlling the activities of the Company and its consolidated group, directly or indirectly, including any director (whether executive or otherwise) of the Company (Directors) or of an entity within the consolidated group) (**Key Management Personnel**), other than the Chair: or

 their closely related parties (including a spouse, child, dependent or other close family members, as well as any companies they control) (Closely Related Parties),

for Item 3 will not be counted unless Shareholders specify how the proxy is to vote.

Any undirected proxy given to the Chair for Item 3 by a Shareholder entitled to vote on such Item will be voted by the Chair in favour of the Item, in accordance with the express authorisation on the Proxy Form (even though Items 3 is connected directly or indirectly with the remuneration of members of Key Management Personnel). The Chair intends to vote all valid undirected proxies for all Items in favour of those Items.

Power of attorney and corporate representatives

If the Proxy Form is signed by an attorney, the power of attorney or a certified copy of it must be sent with the Proxy Form.

A body corporate member may elect to appoint a representative, rather than appoint a proxy. Where a body corporate appoints a representative, written proof of the representative's appointment must be lodged with, or presented to, the Company before the Meeting.

A body corporate appointed as a proxy must also lodge a certificate of appointment of a corporate representative.

The appointment of a corporate representative must be received by the Company before the Meeting or at the registration desk on the day of the Meeting. Certificates of appointment of corporate representatives are available at MUFG Corporate Markets (AU) Limited's website https://www.mpms.mufg.com/en/for-individuals/au/shareholders/forms/ — then submit the form in accordance with the instructions on the 'Appointment of Corporate Representation' form,

or on request by calling +61 1300 554 474.

LODGING PROXY FORMS

Deadline

Proxy Forms must be received by 10:00am (AWST) on Tuesday 18 November 2025.

How to lodge Proxy Forms

You can lodge your Proxy Form with the Company by:

Online: at https://au.investorcentre.mpms.mufg.com

Mail: to Orbital Corporation Limited C/- MUFG Corporate Markets (AU) Limited, Locked Bag A14 Sydney South NSW 1235 Australia.

Delivery: to MUFG Corporate Markets (AU) Limited* Parramatta Square, Level 22, Tower 6, 10 Darcy Street Parramatta NSW 2150

*During business hours Monday to Friday (9:00am - 5:00pm)

Facsimile: +61 2 9287 0309

Further details on how to lodge your Proxy Form can be found on the reverse side of the Proxy Form.

ENQUIRIES

If you have any questions about this Notice or your Proxy Form please contact the Company's share registry, MUFG Corporate Markets (AU) Limited, by calling +61 1300 554 474.

By order of the Board of Directors

Mark Wege Company Secretary
17 October 2025

ITEM 1 CHAIR'S ADDRESS

The Chair will address the Meeting and provide a presentation on the performance of the Company during the financial year ended 30 June 2025 and describe the strategic and operational activities of the Company. The Chair will also allow time at the end of the Meeting to respond to questions by Shareholders.

ITEM 2 DISCUSSION OF FINANCIAL STATEMENTS AND REPORTS

In accordance with the Corporations Act, Shareholders will have a reasonable opportunity to ask questions or make comments on the Company's Financial Report, Directors' Report and Auditor's Report for the year ended 30 June 2025.

The Company's auditor, Nexia Perth Audit Services Pty Ltd will be present at the Meeting and Shareholders will have an opportunity to ask the auditor questions in relation to the conduct of the audit, the Auditor's Report, the Company's accounting policies and the independence of the auditor.

The auditor will also respond to any written questions provided these are submitted to the Company no later than five business days prior to the Meeting.

There is no requirement for Shareholders to approve the Company's Financial Report, Directors' Report and Auditor's Report.

A copy of the Company's 2025 Annual Report, which includes the Company's Financial Report, Directors' Report and Auditor's Report is available on the Company's website: https://www.orbitaluav.com/.

ITEM 3 REMUNERATION REPORT

Background

The Remuneration Report for the financial year ended 30 June 2025 is included in the Company's 2025 Annual Report and sets out the Company's remuneration arrangements for Directors and executive staff.

The Chair will allow a reasonable opportunity for Shareholders to ask questions about or make comments on the Remuneration Report at the Meeting. Shareholders will then be asked to vote on the Remuneration Report.

The vote is advisory only and does not bind the Company or its Directors. The Company's board (**Board**) will consider the outcome of the vote and comments made by Shareholders on the Remuneration Report at the meeting when reviewing the Company's remuneration policies.

No spill resolution

If at least 25% of votes that are cast are voted against the adoption of the Company's Remuneration Report at two consecutive annual general meetings, Shareholders must vote on whether the Board (other than any managing director) should go up for re-election.

At the Company's 2024 annual general meeting, less than 25% of the votes cast on the resolution to adopt the 2024 Remuneration Report were voted against the resolution. Accordingly no spill resolution will be held at this Meeting.

Voting prohibition statement

In accordance with the Corporations Act, a vote on this Item must not be cast (in any capacity) by or on behalf of any of the following persons:

- a member of the Key Management Personnel details of whose remuneration are included in the Remuneration Report; or
- · a Closely Related Party of such a member.

However, a person described above may cast a vote on this Item if the vote is not cast on behalf of a person described in subparagraphs (a) or (b) above and either:

- the person is appointed as a proxy by writing that specifies the way the proxy is to vote on this Item; or
- the person is the Chair and the appointment of the Chair as proxy does
 not specify the way the proxy is to vote on this Item but expressly
 authorises the Chair to exercise the proxy, even if this Item is connected
 directly or indirectly with the remuneration of a member of the Key
 Management Personnel.

Board recommendation

The Board abstains, in the interests of good corporate governance, from making a recommendation in relation to the adoption of the Remuneration Report.

The Chair intends to vote undirected proxies in favour of Item 3 in accordance with the express authorisation on the Proxy Form.

ITEM 4 RE-ELECTION OF DIRECTOR – MR STEVE GALLAGHER

Mr Steve Gallagher was last re-elected to the Board on 16 November 2022.

In accordance with Listing Rule 14.4 and clause 7.3(c) of the Constitution, Mr Gallagher will retire and being eligible, offer himself for re-election as this is the third annual general meeting since he was last elected. His relevant skills and experience and other ASX listed directorships are summarised below.

Mr Steve Gallagher BENG (HON) BCOM MAICD

Term

Initially appointed to the Board on 12 April 2017

Independent

Mr Gallagher is an independent non-executive Director.

Skills and experience

Mr Gallagher is Principal of Agere Pty Ltd, an advisory and investment company drawing on his capability and professional networks established over 30 years as a CEO, director, and executive general manager of global businesses with companies including Vix Technology Ltd, Siemens AG, Landis & Gyr AG and CCRTT Ltd.

Mr Gallagher has operated in various business sectors including industrial automation, building technology and power systems, having spent 15 years living and working in Asia (China, Hong Kong and Singapore) and Europe (Switzerland).

Mr Gallagher is currently a non-executive director and chair of ICM Mobility Ltd (an investment holding company for mobility services companies in transportation including Vix Technology Ltd, Littlepay Ltd, Kuba Payments Ltd, Snapper Services Ltd, Unwire Ltd), Transact1 Pty Ltd (a financial services provider for cash management optimisation), DTI Group Ltd (an ASX listed passenger information and surveillance business).

Other ASX listed directorships

Mr Gallagher also serves as a non-executive director of DTI Group Ltd (ASX: DTI) (originally appointed as a director in October 2018).

Interests in the Company

412,502 Shares.

If Item 4 is passed, Mr Gallagher will be re-elected as a Director.

If Item 4 is not passed, Mr Gallagher will cease to be a Director at the conclusion of the Meeting.

Board recommendation

The Board (other than Mr Gallagher who has an interest in Item 4) believe that the re-election of Mr Gallagher is in the best interests of the Company, as his skills and experience align with the Company's strategic direction, and unanimously recommend that Shareholders vote in favour of the re-election of Mr Gallagher.

The Chair intends to vote undirected proxies in favour of Item 4.

ITEM 5 ELECTION OF DIRECTOR - ANDREW MILLS

In accordance with Listing Rule 14.4 and clause 7.3(j) of the Constitution, a director appointed by the Board as an addition to the board must not hold office (without re-election) past the next annual general meeting following the director's appointment.

Mr Mills, an executive Director, retires in accordance with clause 7.3(j) of the Constitution and Listing Rule 14.4 and offers himself for re-election. Mr Mills joined the Board in January 2025. He is an executive Director.

Mr Andrew Mills
BSc (HON) MAICD

BSC (HON) WATC

Term Appointed to the Board on 9 January 2025.

Independent

Mr Mills is an executive Director.

Skills and experience

Mr Mills has a bachelor's degree in applied chemistry and has 25 years' experience within automotive and aerospace industries. Prior to joining Orbital in 2019 Mr Mills held senior leadership roles with BAE Systems UK and HELLA New Zealand.

Mr Mills previously oversaw Orbital Operations as the general manager of operations and was interim chief executive officer from September 2023 to March 2024.

Mr Mills' significant technical, operational and industry expertise, combined with his oversight of Orbital's aerospace disciplines, was crucial in maturing Orbital's manufacturing capability within the aerospace industry.

Other ASX listed directorships

Nil.

Interests in the Company

3,461 Shares 1,000,000 Options

If Item 5 is passed, Mr Mills will be elected as a Director.

If Item 5 is not passed, Mr Mills will cease to be a Director at the conclusion of the Meeting.

Board recommendation

The Board (other than Mr Mills who has an interest in Item 5) believe that the election of Mr Mills is in the best interests of the Company, as his skills and experience align with the Company's strategic direction, and unanimously recommend that Shareholders vote in favour of the election of Mr Mills.

The Chair intends to vote undirected proxies in favour of Item 5.

ITEM 6 RATIFY THE ISSUE OF PLACEMENT SHARES UNDER LISTING RULE 7.1

Background

In August 2025, the Company undertook a placement to raise \$3 million (before costs) through the issue of 14,285,714 new Shares at an issue price of \$0.21 per Share (**Placement Shares**) (the **Placement**). Refer to the Company's ASX announcement dated 21 August 2025 for further information on the Placement.

All Placement Shares were issued pursuant to the Company's placement capacity under Listing Rule 7.1 without Shareholder approval.

Item 6 seeks Shareholder approval pursuant to Listing Rule 7.4 to ratify the issue of the Placement Shares issued pursuant to the Company's placement capacity under Listing Rule 7.1.

Item 6 is an ordinary resolution.

The Chair intends to exercise all available undirected proxies in favour of Item 6

Voting exclusion statement

The Company will disregard any votes cast in favour of this Item by or on behalf of a person who participated in the Placement or an associate of those persons.

However, this does not apply to a vote cast in favour of this Item by:

- a person as proxy or attorney for a person who is entitled to vote on this Item, in accordance with directions given to the proxy or attorney to vote on this Item that way; or
- the Chair as proxy or attorney for a person who is entitled to vote on this Item, in accordance with a direction given to the Chair to vote on this Item as the Chair decides; or
- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on this Item; and
 - o the holder votes on this Item in accordance with directions given by the beneficiary to the holder to vote in that way.

Listing Rule 7.4

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of Equity Securities that a listed company can issue without the approval of its shareholders over any 12-month period to 15% of the fully paid ordinary securities it had on issue at the start of that period (15% Placement Capacity).

Listing Rule 7.4 provides that if the Company in general meeting ratifies the previous issue of Equity Securities made pursuant to Listing Rule 7.1 (and provided that the previous issue did not breach Listing Rule 7.1) those Equity Securities will be deemed to have been made with Shareholder approval for the purpose of Listing Rule 7.1.

The Company wishes to retain as much flexibility as possible to issue additional Equity Securities into the future up to the 15% Placement Capacity set out in Listing Rule 7.1 without the requirement to obtain prior Shareholder approval.

If Item 6 is passed, the Placement Shares will be excluded in calculating the Company's 15% Placement Capacity in Listing Rule 7.1, effectively increasing the number of Equity Securities the Company can issue without Shareholder approval over the 12-month period from the date of issue.

If Item 6 is not passed, the Placement Shares will be included in calculating the Company's 15% Placement Capacity in Listing Rule 7.1, effectively decreasing the number of Equity Securities the Company can issue without Shareholder approval over the 12-month period from the date of issue.

Specific Information required by Listing Rule 7.5

The following information must be provided to Shareholders for the purposes of obtaining Shareholder approval:

Identity of Shareholders

The Placement Shares were issued to institutional and sophisticated investors identified by Peloton Capital Pty Ltd (who acted as lead manager to the Placement) and the Company, none of whom were a related party of the Company, a member of the Key Management Personnel, a substantial shareholder of the Company, or an adviser of the Company or an associate of any of those persons.

Type of securities

The Placement Shares are fully paid ordinary shares in the capital of the Company and rank equally in all respects with the Company's existing Shares on issue.

Date of issue

The Placement Shares were issued on 28 August 2025.

Issue price

The Placement Shares were issued at an issue price of \$0.21 per Share, raising a total of approximately \$3 million (before costs).

of funds

Indicative use Funds raised from the issue of the Placement Shares are intended to upgrade and increase the Company's manufacturing and test facilities, increase global business development activities and accelerate the development of new product offers.

agreement

Terms of the The Placement Shares were issued pursuant to placement letters pursuant to which institutional and sophisticated investors agreed to participate in the Placement. The key terms of the placement letters have been disclosed in this

Voting exclusion statement

A voting exclusion statement is included above.

Board recommendation

The Board unanimously recommends that Shareholders vote in favour of Item 6.

The Chair intends to vote undirected proxies in favour of Item 6.

ITEM 7 ADDITIONAL CAPACITY TO ISSUE EQUITY **SECURITIES**

General

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of Equity Securities that a listed company can issue without the approval of its shareholders over any 12 month period to 15% of the fully paid ordinary securities it had on issue at the start of that period.

Listing Rule 7.1A enables eligible entities to issue Equity Securities up to 10% of its issued share capital through placements over a 12-month period after the annual general meeting (being the 10% Placement Facility). The 10% Placement Facility is in addition to the Company's 15% Placement Capacity under Listing Rule 7.1.

An eligible entity for the purposes of Listing Rule 7.1A is an entity that is not included in the S&P/ASX 300 Index and has a market capitalisation of \$300 million or less. The Company is an eligible entity.

The Company is seeking Shareholder approval by way of a special resolution to have the ability to issue Equity Securities under the 10% Placement Facility. The number of Equity Securities to be issued under the 10% Placement Facility will be determined in accordance with the formula prescribed in Listing Rule 7.1A.

If Item 7 is passed, the effect will be that the Company will be able to issue Equity Securities under the 10% Placement Facility in addition to the Company's 15% Placement Capacity under Listing Rule 7.1.

If Item 7 is not passed, the effect will be that the Company will not be able to issue any Equity Securities under the 10% Placement Facility and will have to rely upon its 15% Placement Capacity under Listing Rule 7.1 for the issue of Equity Securities.

Item 7 is a special resolution and therefore requires approval of 75% of the votes cast by Shareholders present and eligible to vote (in person, by proxy, by attorney or, in the case of a corporate Shareholder, by a corporate representative).

Voting exclusion statement

The Company will disregard any votes cast in favour of Item 7 by or on behalf of a person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person (or those persons).

However, this does not apply to a vote cast in favour of this Item 7 by:

- a person as proxy or attorney for a person who is entitled to vote on this Item, in accordance with directions given to the proxy or attorney to vote on this Item in that way; or
- the Chair as proxy or attorney for a person who is entitled to vote on the Item, in accordance with a direction given to the Chair to vote on the Item as the Chair decides; or
- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on this Item; and
 - the holder votes on this Item in accordance with directions given by the beneficiary to the holder to vote in that way.

As at the date of this Notice, the Company has not identified any particular persons or class of persons who would be excluded from voting on Item 7.

Listing Rule 7.1A

Shareholder approval (a)

The ability to issue Equity Securities under the 10% Placement Facility is subject to Shareholder approval by way of a special resolution at an annual general meeting.

Equity Securities (b)

Any Equity Securities issued under the 10% Placement Facility must be in the same class as an existing quoted class of Equity Securities of the company.

The Company, as at the date of this Notice, has on issue two quoted classes of Equity Securities, being Shares and Options.

Formula for calculating 10% Placement Facility (c)

Listing Rule 7.1A.2 provides that eligible entities that have obtained Shareholder approval at an annual general meeting may issue or agree to issue, during the 12 month period after the date of the annual general meeting, a number of Equity Securities calculated in accordance with the following formula:

$$(A \times D) - E$$

A is the number of fully paid ordinary securities on issue 12 months before the date of issue or agreement:

- plus the number of fully paid ordinary securities issued in the 12 months under an exception in Listing Rule 7.2 (other than exception 9, 16 or 17).
- (ii) plus the number of fully paid ordinary securities issued in the 12 months on the conversion of convertible securities within rule 7.2 (exception 9) where:
 - the convertible securities were issued or agreed to be issued before the commencement of the 12 months; or
 - (B) the issue of, or agreement to issue, the convertible securities was approved, or taken under the Listing Rules to have been approved, under Listing Rule 7.1 or Listing Rule 7.4,
- (iii) plus the number of fully paid ordinary securities issued in the 12 months under an agreement to issue securities within Listing Rule 7.2 (exception 16) where:
 - (A) the agreement was entered into before the commencement of the relevant period; or
 - (B) the agreement or issue was approved or taken under the Listing Rules to have been approved under Listing Rule 7.1 or Listing Rule 7.4,
- (iv) plus the number of any other fully paid ordinary securities issued in the 12 months with approval under Listing Rule 7.1 or Listing Rule 7.4 (noting that this may include fully paid ordinary securities issued in the 12 months under an agreement to issue securities within Listing Rule 7.2 (exception 17) where the issue is subsequently approved under Listing Rule 7.1),
- (v) plus the number of partly paid ordinary securities that became fully paid in the 12 months,
- (vi) less the number of fully paid ordinary securities cancelled in the 12 months.

Note that A has the same meaning in Listing Rule 7.1 when calculating an entity's 15% Placement Capacity.

D is 10%

E is the number of Equity Securities issued or agreed to be issued under Listing Rule 7.1A.2 in the 12 months where the issue or agreement to issue has not been subsequently approved by Shareholders under Listing Rule 7.4.

(d) Listing Rule 7.1 and Listing Rule 7.1A

The ability of an entity to issue Equity Securities under Listing Rule 7.1A is in addition to the entity's 15% Placement Capacity under Listing Rule 7.1.

The number of Equity Securities that the Company will have capacity to issue under Listing Rule 7.1A (if Item 7 is approved) will be calculated at the date of issue of the Equity Securities in accordance with the formula prescribed in Listing Rule 7.1A.2 (refer to section (c) above).

(e) Minimum Issue Price

The issue price of Equity Securities to be issued under Listing Rule 7.1A must be not less than 75% of the VWAP of Equity Securities in the same class calculated over the 15 trading days on which trades in that class were recorded immediately before:

- the date on which the price at which the Equity Securities are to be issued is agreed by the Company and the recipient of the Equity Securities; or
- (ii) if the Equity Securities are not issued within 10 trading days of the date in paragraph (i) above, the date on which the Equity Securities are issued.

(f) 10% Placement Period

Shareholder approval of the 10% Placement Facility under Listing Rule 7.1A is valid from the date of the annual general meeting at which the approval is obtained and expires on the first to occur of the following:

- (i) The date that is 12 months after the date of the annual general meeting at which the approval is obtained.
- (ii) The time and date of the entity's next annual general meeting.
- (iii) The time and date of Shareholder approval of a transaction under Listing Rule 11.1.2 (a significant change to the nature or scale of activities) or Listing Rule 11.2 (disposal of main undertaking),

(the 10% Placement Period).

Effect of Item 7

The effect of Item 7 will be to allow the Directors to issue the Equity Securities under Listing Rule 7.1A during the 10% Placement Period without using the Company's 15% Placement Capacity under Listing Rule 7.1.

Specific Information required by Listing Rule 7.3A

Shareholder The 10% Placement Facility under Item 7 will be valid (if that approval Item is passed) during the 10% Placement Period as detailed expiry in section (f) above.

Minimum issue price

The Equity Securities under the 10% Placement Facility will be issued at an issue price of not less than 75% of the VWAP for the same class of the Company's Equity Securities over the 15 trading days on which trades in that class were recorded immediately before:

- the date on which the price at which the Equity Securities are to be issued is agreed; or
- if the Equity Securities are not issued within 10 trading days of the date in the paragraph immediately above, the date on which the Equity Securities are issued.

Indicative The Company may seek to issue the Equity Securities for use of funds cash consideration, which may be utilised for the acquisition of new businesses or investments, operating expenditures and/or general working capital.

Risk of Dilution

If Item 7 is approved by Shareholders and the Company issues Equity Securities under the 10% Placement Facility, the existing Shareholders' voting power in the Company will be diluted as shown in the table in **Schedule 1** (in the case of listed Options, if the listed Options are exercised).

There is a risk of economic and voting dilution to the Shareholders, including that:

- the market price for the Company's Equity Securities in that class may be significantly lower on the date of the issue of the Equity Securities than on the date of the Meeting; and
- the Equity Securities may be issued at a price that is at a discount to the market price for the Company's Equity Securities on the issue date.

The table in **Schedule 1** shows the dilution of existing Shareholders on the basis of the current market price of Shares and the current number of Shares for variable 'A' calculated in accordance with the formula in Listing Rule 7.1A.2 as at the date of this Notice.

The table also shows:

- two examples where variable 'A' has increased, by 50% and 100%. Variable 'A' is based on the number of ordinary securities the Company has on issue. The number of ordinary securities on issue may increase as a result of issues of ordinary securities that do not require Shareholder approval (for example, a pro rata entitlements issue or scrip issued under a takeover offer) or future specific placements under Listing Rule 7.1 that are approved at a future Shareholders' meeting; and
- two examples of where the issue price of ordinary securities has decreased by 50% and increased by 100% as against the current market price.

Listing Rules disclosures The Company will comply with its disclosure obligations under Listing Rules 7.1A.4, 2.7 and 3.10.3 in relation to any issue of securities under the 10% Placement Facility.

Allocation policy

The Company's allocation policy is dependent on the prevailing market conditions at the time of any proposed issue pursuant to the 10% Placement Facility. The identity of subscribers for Equity Securities pursuant to the 10% Placement Facility will be determined on a case-by-case basis having regard to factors which may include (but not limited to) the following:

- · the purpose of the issue;
- the methods of raising funds that are available to the Company, including (but not limited to) rights issues or other issues in which existing security holders can participate;
- the effect of the issue of the Equity Securities on the control of the Company;
- the financial situation and solvency of the Company;
- · prevailing market conditions; and
- advice from corporate, financial and broking advisers (if applicable).

As at the date of this Notice, the subscribers under the 10% Placement Facility have not been determined. They may, however, include existing substantial Shareholders and/or new Shareholders who are not a related party or an associate of a related party of the Company and are likely to be sophisticated and/or professional investors.

Utilisation in the preceding 12 months

During the period commencing 12 months before the date of the Meeting and ending on the date of this Notice, the Company has not issued, nor agreed to issue, any Equity Securities pursuant to Listing Rule 7.1A.2.

Voting exclusion statement

A voting exclusion statement is included above. However as at the date of this Notice, the Company has not invited any investor to participate in any proposed issue of Equity Securities under Listing Rule 7.1A. Therefore, no existing Shareholders are anticipated to be excluded from voting on this Item.

Previous approval

At the Company's 2024 annual general meeting, Shareholders approved the Company's capacity to issue Equity Securities equivalent to an additional 10% of the Company's ordinary securities. The approval given at the 2024 annual general meeting will expire on 14 November 2025.

Board recommendation

The Board unanimously recommends that Shareholders vote **in favour** of granting the Company the 10% Placement Facility.

The Chair intends to vote undirected proxies in favour of Item 7.

Orbital Corporation Limited SCHEDULE 1 – Listing Rule 7.1A Dilution Table

- (a) The below table shows the dilution of existing Shareholders on the basis of the current market price of Shares and the current number of Shares for variable 'A' (but on the pro forma assumption that variable 'A' is the number of Shares on issue as at the date of the Notice) calculated in accordance with the formula in Listing Rule 7.1A.2 as at the date of this Notice.
- (b) The table also shows:
 - (i) two examples where variable 'A' has increased, by 50% and 100%. Variable 'A' is based on the number of ordinary securities the Company has on issue. The number of ordinary securities on issue may increase as a result of issues of ordinary securities that do not require Shareholder approval (for example, a pro rata entitlements issue or scrip issued under a takeover offer) or future specific placements under Listing Rule 7.1 that are approved at a future Shareholders' meeting; and
 - (ii) two examples of where the issue price of ordinary securities has decreased by 50% and increased by 100% as against the current market price.

Variable 'A' in Listing Rule 7.1A.2	le 'A' in Listing Rule 7.1A.2		Dilution		
		\$[0.135] 50% decrease in Issue Price	\$[0.270] Issue Price	\$[0.54] 100% increase in Issue Price	
Current Variable A (179,065,431 Shares)	10% Voting Dilution	17,906,543	17,906,543	17,906,543	
(173,000,401 Oliales)	Funds Raised	\$2,417,383	\$4,834,767	\$9,669,533	
50% increase in current Variable A (268,598,146 Shares)	10% Voting Dilution	26,859,815	26,859,815	26,859,815	
(200,330, 140 Stiates)	Funds Raised	\$3,626,075	\$7,252,150	\$14,504,300	
100% increase in current Variable A (358,130,862 Shares)	10% Voting Dilution	35,813,086	35,813,086	35,813,086	
	Funds Raised	\$4,834,767	\$9,669,533	\$19,339,066	

The table has been prepared on the following assumptions:

- (a) The Company issues the maximum number of Equity Securities available under the 10% Placement Facility (and, if they are listed Options, they are all converted into Shares).
- (b) No convertible securities are exercised or converted into Shares before the date of the issue of the Equity Securities.
- (c) The 10% voting dilution reflects the aggregate percentage dilution against the issued share capital at the time of issue. This is why the voting dilution is shown in each example as 10%.
- (d) The table does not show an example of dilution that may be caused to a particular Shareholder by reason of placements under the 10% Placement Facility, based on that Shareholder's holding at the date of the Meeting.
- (e) The table shows only the effect of issues of Equity Securities under Listing Rule 7.1A, not under the 15% Placement Capacity under Listing Rule 7.1.
- (f) The issue of Equity Securities under the 10% Placement Facility consists of Shares, or to the extent the issue of Equity Securities includes listed Options (for example, such as the class of existing Options which is currently quoted on the ASX), it is assumed that those listed Options are exercised into Shares for the purpose of calculating the voting dilution effect on existing Shareholders.
- (g) The issue price is \$0.27 being the closing price of the Shares on ASX on 8 October 2025. The Company will only issue the Equity Securities during the 10% Placement Period.



Orbital Corporation Limited ABN 32 009 344 058

LODGE YOUR VOTE

ONLINE

https://au.investorcentre.mpms.mufg.com

BY MAIL

Orbital Corporation Limited C/- MUFG Corporate Markets (AU) Limited Locked Bag A14 Sydney South NSW 1235 Australia

BY FAX

+61 2 9287 0309

Ť

BY HAND

MUFG Corporate Markets (AU) Limited Parramatta Square, Level 22, Tower 6, 10 Darcy Street, Parramatta NSW 2150

1

ALL ENQUIRIES TO

Telephone: +61 1300 554 474



X9999999999

PROXY FORM

I/We being a member(s) of Orbital Corporation Limited and entitled to attend and vote hereby appoint:

APPOINT A PROXY

the Chair of the Meeting (mark box) **OR** if you are **NOT** appointing the Chair of the Meeting as your proxy, please write the name of the person or body corporate you are appointing as your proxy

or failing the person or body corporate named, or if no person or body corporate is named, the Chair of the Meeting, as my/our proxy to act on my/our behalf (including to vote in accordance with the following directions or, if no directions have been given and to the extent permitted by the law, as the proxy sees fit) at the Annual General Meeting of the Company to be held at 10:00am (AWST) on Thursday, 20 November 2025 at the Stirling Leisure Centre, 38 Ashbury Crescent, Mirrabooka WA 6061 (the Meeting) and at any postponement or adjournment of the Meeting.


Important for Item 3: If the Chair of the Meeting is your proxy, either by appointment or by default, and you have not indicated your voting intention below, you expressly authorise the Chair of the Meeting to exercise the proxy in respect of Item 3, even though the Item is connected directly or indirectly with the remuneration of a member of the Company's Key Management Personnel (**KMP**).

The Chair of the Meeting intends to vote undirected proxies in favour of each item of business.

VOTING DIRECTIONS

Proxies will only be valid and accepted by the Company if they are signed and received no later than 48 hours before the Meeting. Please read the voting instructions overleaf before marking any boxes with an \boxtimes

	• •	
Items	For Against Abstain*	For Against Abstain*
3 Remuneration Report	7 Additional Capacity to issue Equity Securities	
4 Re-Election of Director – Mr Steve Gallagher		
5 Election of Director – Mr Andrew Mills		
6 Ratify the Issue of Placement Shares under Listing Rule 7.1		
	 3 Remuneration Report 4 Re-Election of Director – Mr Steve Gallagher 5 Election of Director – Mr Andrew Mills 6 Ratify the Issue of Placement Shares 	3 Remuneration Report 7 Additional Capacity to issue Equity Securities 4 Re-Election of Director – Mr Steve Gallagher 5 Election of Director – Mr Andrew Mills 6 Ratify the Issue of Placement Shares



SIGNATURE OF SHAREHOLDERS – THIS MUST BE COMPLETED

Shareholder 1 (Individual) Joint Shareholder 2 (Individual) Joint Shareholder 3 (Individual)

Sole Director and Sole Company Secretary Director/Company Secretary (Delete one) Director

This form should be signed by the shareholder. If a joint holding, either shareholder may sign. If signed by the shareholder's attorney, the power of attorney must have been previously noted by the registry or a certified copy attached to this form. If executed by a company, the form must be executed in accordance with the company's constitution and the *Corporations Act 2001* (Cth).

* If you mark the Abstain box for a particular Item, you are directing your proxy not to vote on your behalf on a show of hands or on a poll and your



HOW TO COMPLETE THIS SHAREHOLDER PROXY FORM

YOUR NAME AND ADDRESS

This is your name and address as it appears on the Company's share register. If this information is incorrect, please make the correction on the form. Shareholders sponsored by a broker should advise their broker of any changes. Please note: you cannot change ownership of your shares using this form.

APPOINTMENT OF PROXY

If you wish to appoint the Chair of the Meeting as your proxy, mark the box in Step 1. If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that individual or body corporate in Step 1. A proxy need not be a shareholder of the Company.

DEFAULT TO CHAIR OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote those proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Form, including where the Item is connected directly or indirectly with the remuneration of KMP

VOTES ON ITEMS OF BUSINESS – PROXY APPOINTMENT

You may direct your proxy how to vote by placing a mark in one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF A SECOND PROXY

You are entitled to appoint up to two persons as proxies to attend the Meeting and vote on a poll. If you wish to appoint a second proxy, an additional Proxy Form may be obtained by telephoning the Company's share registry or you may copy this form and return them both together.

To appoint a second proxy you must:

- (a) on each of the first Proxy Form and the second Proxy Form state the percentage of your voting rights or number of shares applicable to that form. If the appointments do not specify the percentage or number of votes that each proxy may exercise, each proxy may exercise half your votes. Fractions of votes will be disregarded; and
- (b) return both forms together.

SIGNING INSTRUCTIONS

You must sign this form as follows in the spaces provided:

Individual: where the holding is in one name, the holder must sign.

Joint Holding: where the holding is in more than one name, either shareholder may sign.

Power of Attorney: to sign under Power of Attorney, you must lodge the Power of Attorney with the registry. If you have not previously lodged this document for notation, please attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the Corporations Act 2001) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please indicate the office held by signing in the appropriate place.

CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate "Certificate of Appointment of Corporate Representative" must be received at support@cm.mpms.mufg.com prior to admission in accordance with the Notice of Annual General Meeting. A form of the certificate may be obtained from the Company's share registry or online at www.mpms.mufg.com/en/mufg-corporate-markets.

LODGEMENT OF A PROXY FORM

This Proxy Form (and any Power of Attorney under which it is signed) must be received at an address given below by 10:00am (AWST) on Tuesday, 18 November 2025, being not later than 48 hours before the commencement of the Meeting. Any Proxy Form received after that time will not be valid for the scheduled Meeting.

Proxy Forms may be lodged using the reply paid envelope or:



ONLINE

https://au.investorcentre.mpms.mufg.com

Login to the Investor Centre using the holding details as shown on the Voting/Proxy Form. Select 'Voting' and follow the prompts to lodge your vote. To use the online lodgement facility, shareholders will need their "Holder Identifier" - Securityholder Reference Number (SRN) or Holder Identification Number (HIN).



BY MOBILE DEVICE

Our voting website is designed specifically for voting online. You can now lodge your vote by scanning the QR code adjacent or enter the voting link

https://au.investorcentre.mpms.mufg.com into your mobile device. Log in using the Holder Identifier and postcode for your shareholding.



To scan the code you will need a QR code reader application which can be downloaded for free on your mobile device.



BY MAIL

Orbital Corporation Limited C/- MUFG Corporate Markets (AU) Limited Locked Bag A14 Sydney South NSW 1235 Australia



BY FAX

+61 2 9287 0309



BY HAND

delivering it to MUFG Corporate Markets (AU) Limited* Parramatta Square

Level 22, Tower 6

10 Darcy Street

Parramatta NSW 2150

*during business hours Monday to Friday (9:00am - 5:00pm)







COMMUNICATIONS PREFERENCE

We encourage you to receive all your shareholder communications via email. This communication method allows us to keep you informed without delay, is environmentally friendly and reduces print and mail costs.



ONLINE

https://au.investorcentre.mpms.mufg.com

Login to the Investor Centre using the holding details as shown on the Proxy Form. Select 'Communications' and click the first button to receive all communications electronically and enter your email address. To use the online facility, securityholders will need their "Holder Identifier" (Securityholder Reference Number (SRN) or Holder Identification Number (HIN) as shown on the front of the Proxy Form).